Call Center: 1-(918) 928-5781

Stem cells from umbilical cord blood may help treat eczema

Date:

   June 7, 2016

Source:

   Wiley

Summary:

A new study suggests that treatment with stem cells from umbilical cord blood might be an effective therapy for patients with moderate-to-severe eczema, or atopic dermatitis. For the clinical trial, 34 patients were randomly assigned to receive a low dose or high dose of the cells subcutaneously. Fifty five percent of patients who received the high dose showed a 50% reduction in what’s known as the Eczema Area and Severity Index score at week 12.

A new study suggests that treatment with stem cells from umbilical cord blood might be an effective therapy for patients with moderate-to-severe eczema, or atopic dermatitis.

For the clinical trial, 34 patients were randomly assigned to receive a low dose or high dose of the cells subcutaneously.

Fifty five percent of patients who received the high dose showed a 50% reduction in what's known as the Eczema Area and Severity Index score at week 12. Immune-related markers of atopic dermatitis also decreased significantly.

"This study is a first-in-class study demonstrating that adults with moderate-to-severe atopic dermatitis responded to a treatment of stem cells derived from umbilical cord blood," said Dr. Tae-Yoon Kim, senior author of the Stem Cells study. "The single treatment of stem cells in patients resulted in the significant and persistent improvement in disease symptoms throughout the follow-up period of 12 weeks."

The study was conducted at Seoul St. Mary's Hospital in collaboration with Seoul National University (with co-senior author, Dr. Kyung-Sun Kang).

Story Source:

The above post is reprinted from materials provided by Wiley. Note: Materials may be edited for content and length.

Journal Reference:

   Hyung-Sik Kim, Ji Hyun Lee, Kyoung-Hwan Roh, Hee Jin Jun, Kyung-Sun Kang, Tae-Yoon Kim. Clinical Trial of Human Umbilical Cord Blood-derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies. STEM CELLS, 2016; DOI: 10.1002/stem.2401

Contacts

1-(918) 928-5781

 Email: info@trueviewbiotech.com

 Skype: stemcelltreatmentcenter